Abstract
Background
Asprosin is an emerging biomarker that plays a role in metabolic diseases. This study investigates asprosin as a predictive marker for coronary artery disease (CAD) severity in diabetic patients.
Methods
Diabetic patients (n = 181) and healthy controls (n = 60) were analyzed. CAD severity was assessed using SYNTAX score. Diabetic patients were divided into 3 groups. Group 1 = patients without CAD, group 2 = patients with low SYNTAX score, and group 3 = patients with moderate-high SYNTAX score. Asprosin levels were measured for all participants using an enzyme-linked immunosorbent assay (ELISA).
Results
Asprosin levels were significantly higher in patient group compared to control group (p < 0.001). Asprosin levels were significantly higher in group 3 compared to group 1 and group 2 (p = 0.002). In logistic regression analysis, asprosin levels independently predicted patients with moderate-high SYNTAX scores. According to this analysis, 1 ng/mL increase in asprosin level was found to increase the risk of having moderate-high SYNTAX score by 14.1%. When the threshold value of asprosin level was set as 22.17 ng/mL, it predicted patients with moderate-high SYNTAX score with 63.6% sensitivity and 62.6% specificity. In multivariate regression analysis, SYNTAX score independently correlated with asprosin level.
Conclusion
This is the first study in the literature to demonstrate a positive correlation between asprosin levels and SYNTAX scores in diabetic patients with CAD. More comprehensive studies with larger groups are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Committee ADAPP 2 (2021) Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care 45(Supplement_1):S17–S38
Romere C, Duerrschmid C, Bournat J et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165(3):566–579. https://doi.org/10.1016/j.cell.2016.02.063
Yuan M, Li W, Zhu Y et al (2020) Asprosin: a novel player in metabolic diseases. Front Endocrinol (Lausanne). 11:64. https://doi.org/10.3389/fendo.2020.00064
Farrag M, Eldjoudi DA, González-Rodríguez M et al (2023) Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol (Lausanne). 13:1101091. https://doi.org/10.3389/fendo.2022.1101091
Grundy SM, Benjamin IJ, Burke GL et al (2000) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10):1134–1146. https://doi.org/10.1161/01.cir.100.10.1134
Moradi N, Fouani FZ, Vatannejad A et al (2021) Serum levels of asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study. Lipids Health Dis 20(1):88. https://doi.org/10.1186/s12944-021-01514-9
Güven C, Kafadar H (2022) Evaluation of plasma asprosin concentration in patients with coronary artery disease. Braz J Cardiovasc Surg 37(4):493–500. https://doi.org/10.21470/1678-9741-2021-0003
Sianos G, Morel M-A, Kappetein AP et al (2005) The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227
Serruys PW, Morice M-C, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972. https://doi.org/10.1056/NEJMoa0804626
Acara AÇ, Bolatkale M, Kızıloğlu İ et al (2018) A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med 36(8):1504–1505. https://doi.org/10.1016/j.ajem.2017.12.032
Zhang Z, Tan Y, Zhu L et al (2019) Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci 231:116554. https://doi.org/10.1016/j.lfs.2019.116554
Wen M-S, Wang C-Y, Yeh J-K et al (2020) The role of asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord 20(1):402. https://doi.org/10.1186/s12872-020-01680-1
Feng J, Yang Y, Yang Y et al (2018) GW29-e0080 the protective role of asprosin against diabetes in cardiomyocytes. J Am Coll Cardiol 72(16S):C2. https://doi.org/10.1016/j.jacc.2018.08.012
Chen S, Wang X, Qiu CM et al (2019) Study of the role and mechanism of asprosin/spartin pathway in cardiac microvascular endothelial injury induced by diabete mellitus. Sichuan da xue xue bao Yi xue ban= J Sichuan Univ (Med Sci Ed) 50(6):827–834
Kundu A, Sardar P, O’Day K et al (2018) SYNTAX score and outcomes of coronary revascularization in diabetic patients. Curr Cardiol Rep 20(5):28. https://doi.org/10.1007/s11886-018-0971-1
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Contributions
Concept/design: IY, EG, DD, TS, HES; analysis/interpretation: IY, EG, MLA, FAB, HAO, FNA; data acquisition: IY, EG, MLA, FAB, HAO, FNA; writing: IY, EG, HES; critical revision: IY, EG, DD, TS, HES; final approval: IY, EG, DD, TS, HES.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yigitdol, I., Gulumsek, E., Demirtas, D. et al. The role of serum asprosin levels in predicting the severity of coronary artery disease in patients with diabetes mellitus. Ir J Med Sci (2024). https://doi.org/10.1007/s11845-024-03616-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11845-024-03616-6